Alzinova starts ALZ-101 Phase II and launches ~$5.5M rights issue
Alzinova began Phase II operational start-up for ALZ-101 in early Alzheimer’s, targeting ~120 patients, with first patient expected around late 2026/early 2027. The company also launched a rights issue of approximately $5.5M to fund initiation and CMC.
Alzinova has begun the Phase II operational start-up for ALZ-101 in early Alzheimer’s, with the trial targeting about 120 patients. The company said the first patient is expected around late 2026 or early 2027. Alzinova also launched a rights issue of approximately $5.5M to fund the trial initiation and CMC.